Adeel Shibli, MD
Pulmonary Disease · Mesquite, TXNPI 1427182872
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.4% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 37.8% of the total. Reporting peaked in 2019 at $122 and has fallen 79.9% since, to $25 in 2025. That places this record below the midpoint for pulmonary disease clinicians in TX, where the typical reported total is $1,976.
Across 16 payments — averaging $14.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$86
- Gilead$39
- Sanofi Pasteur Inc.$36
- Medivance, Inc.$29
- Pfizer$25
- Merck$13
Across 2 payments — averaging $10,504 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$21K
What the payments were for
- Food & beverage$21594%
- Education$136%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 9 | $86 |
| Gilead | 2 | $39 |
| Sanofi Pasteur Inc. | 2 | $36 |
| Medivance, Inc. | 1 | $29 |
| Pfizer | 1 | $25 |
| Merck | 1 | $13 |
How this compares
$228 in reported general payments places this provider in the 20th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 249 | $184,730 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 144 | $96,612 |
| Spiriva HandihalerTiotropium Bromide | 68 | $37,149 |
| SymbicortBudesonide/Formoterol Fumarate | 100 | $27,405 |
| Breo ElliptaFluticasone/Vilanterol | 65 | $24,088 |
| Advair HfaFluticasone Propion/Salmeterol | 42 | $17,734 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $14,937 |
| Incruse ElliptaUmeclidinium Bromide | 46 | $14,291 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 606 | $14,163 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $12,319 |
| Arnuity ElliptaFluticasone Furoate | 22 | $7,513 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 78 | $6,382 |
| BreynaBudesonide/Formoterol Fumarate | 15 | $2,614 |
| Roflumilast | 58 | $2,546 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $2,170 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Mesquite
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
- David MarksSan Antonio$453K
- Sandeep SahayHouston$378K
- Jefy MathewThe Woodlands$318K
- Rodolfo Estrada AnzuetoSan Antonio$300K
- Zeenat SafdarHouston$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.